Form 4: Director Eugene A. Woods Receives JNJ Deferred Share Units
Statement of Changes in Beneficial Ownership
Johnson & Johnson director Eugene A. Woods was granted 975 deferred share units as part of the company's director compensation plan.
Summary
- Director Eugene A. Woods acquired 975 Deferred Share Units (DSUs) on April 23, 2026.
- The DSUs were granted under the Johnson & Johnson Amended and Restated Deferred Fee Plan for Directors.
- These units are to be settled in cash upon the termination of the reporting person's directorship.
- The total number of DSUs beneficially owned by the director following this transaction is 6,215.094.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.
Positives
- The transaction reflects standard director compensation practices aligned with long-term equity retention.
Negatives
- None.
Risks
- The value of the deferred share units is tied to the future performance of Johnson & Johnson common stock.
Future Outlook
The deferred share units will be settled in cash upon the termination of the reporting person's directorship, with the value determined by the fair market value of common stock at that time.
Industry Context
StockSavvy.ai notes that this is a routine disclosure of director compensation, consistent with standard corporate governance practices for large-cap pharmaceutical companies.
Comparison to Industry Standards
- The use of deferred share units for director compensation is a standard practice among S&P 500 companies to align director interests with long-term shareholder value.
- The disclosure complies with SEC Section 16(a) reporting requirements for corporate insiders.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of deferred share units under the Amended and Restated Deferred Fee Plan for Directors. | 2026-04-23 | Standard alignment of director interests with company performance. |
Stakeholder Impact
- No material impact on shareholders, employees, or creditors as this is a routine compensation disclosure.
Next Steps
- The reporting person will continue to hold the deferred share units until the termination of their directorship.
Key Dates
| Date | Description |
|---|---|
| 2025-12-07 | Date of Power of Attorney execution. |
| 2026-04-23 | Date of the earliest transaction involving the grant of deferred share units. |
| 2026-04-27 | Date of filing for the Form 4. |
Keywords
Johnson & Johnson, JNJ, Director Compensation, Deferred Share Units, Insider Transaction, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.